SIAH proteins: critical roles in leukemogenesis (Q38049544)

27 August 2017

title

SIAH proteins: critical roles in leukemogenesis (English)

1 reference

27 August 2017

2

1 reference

27 August 2017

O H Krämer

1

1 reference

27 August 2017

G Bug

series ordinal

3

1 reference

27 August 2017

J Hartkamp

series ordinal

4

1 reference

27 August 2017

S K Knauer

series ordinal

5

1 reference

27 August 2017

publication date

5 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

27

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

792-802

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2012.284

27 August 2017

exact match

0 references

cites work

HDACi--targets beyond chromatin.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Targeting the ubiquitin system in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

E2s: structurally economical and functionally replete

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The molecular signature of oncofusion proteins in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Proteasome inhibitors in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Inhibitors of HDACs--effective drugs against cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Siah proteins: novel drug targets in the Ras and hypoxia pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Interaction of AF4 wild-type and AF4.MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Siah-1S, a novel splice variant of Siah-1 (seven in absentia homolog), counteracts Siah-1-mediated downregulation of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Differential regulation of PML-RARα stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Siah1/SIP regulates p27(kip1) stability and cell migration under metabolic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Siah1 interacts with the scaffold protein POSH to promote JNK activation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Eukaryotic translation elongation factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

SIAH-1 interacts with mammalian polyhomeotic homologues HPH2 and affects its stability via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The molecular programme of tumour reversion: the steps beyond malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Normal p53 function in primary cells deficient for Siah genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

E2F1 represses beta-catenin/TCF activity by direct up-regulation of Siah1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Dimerization of hSiah proteins regulates their stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

USP13 enzyme regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Stabilization of HIPK2 by escape from proteasomal degradation mediated by the E3 ubiquitin ligase Siah1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Regulation of the ring finger E3 ligase Siah2 by p38 MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

HDAC2: a critical factor in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Generation and analysis of Siah2 mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Modulation of multidrug resistance in cancer cells by the E3 ubiquitin ligase seven-in-absentia homologue 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Inactivating mutations of the Siah-1 gene in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Mechanisms of leukemogenesis by MLL fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The super elongation complex (SEC) and MLL in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Enforced expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the hematopoietic repopulating cell function and clonogenic potential but is not sufficient to initiate leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

New insights to the MLL recombinome of acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

PAFc, a key player in MLL-rearranged leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Cell-based analysis of structure-function activity of threonine aspartase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The importin-alpha/nucleophosmin switch controls taspase1 protease function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Targeting Taspase1 for cancer therapy--letter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Gatekeeper function of the RUNX1 transcription factor in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Genome-wide functions of PML-RARα in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Review: genetic models of acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Regulation of BOB.1/OBF.1 stability by SIAH

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Identification of AML1-ETO modulators by chemical genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

hSiah2 is a new Vav binding protein which inhibits Vav-mediated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Structural and functional alterations of FLT3 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Flt3 receptor tyrosine kinase as a drug target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Discovery and characterization of novel mutant FLT3 kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

BAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The Ski protein negatively regulates Siah2-mediated HDAC3 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Ski can negatively regulates macrophage differentiation through its interaction with PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

MicroRNA29a regulates the expression of the nuclear oncogene Ski.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Deconstructing repression: evolving models of co-repressor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Role of misfolded N-CoR mediated transcriptional deregulation of Flt3 in acute monocytic leukemia (AML)-M5 subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Hexachlorophene suppresses beta-catenin expression by up-regulation of Siah-1 in EBV-infected B lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Regulation of 2-oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

HtrA2, taming the oncogenic activities of WT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

inferred from DOI database lookup

7 January 2021

based on heuristic

Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.284

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.284

1 reference

Dimensions Publication ID

27 August 2017

1026435759

0 references

1 reference